AstraZeneca Opens Clinical Research Facility In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - AstraZeneca opened its first Chinese Clinical Pharmacology Unit (CPU) Sept. 4, partnering with Peking University on a facility that will focus on Phase I research of therapies targeting infections, diabetes and cardiovascular diseases